Clinical trials: Adult Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome, Acute Lung Injury
Efficacy Study of CytoSorb Hemoperfusion Device on IL-6 Removal in ARDS/ALI Patients With Sepsis
The hypothesis of this study is use of CytoSorb hemoperfusion device as an adjunctive therapy to the standard of care in treating ARDS/ALI patients in the setting of sepsis will result in improved clearance of cytokines when…
- Conditions
- Acute Respiratory Distress Syndrome, Acute Lung Injury, Sepsis
- Trial name
- NCT00559130
- Testing
- CytoSorb Hemoperfusion
- Where
- 6 sites in Germany
- Volunteers
- 100 people
- Sponsor
- MedaSorb Technologies, Inc
Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Efficacy and Safety of Itolizumab in COVID-19 Complications
Randomized, Parallel Group, Active Controlled Trial
- Conditions
- Acute Respiratory Distress Syndrome, Cytokine Release Syndrome, Covid19
- Trial name
- NCT04475588
- Testing
- Itolizumab IV infusion, Best supportive care (BSC)
- Where
- 4 sites in India
- Volunteers
- 32 people
- Sponsor
- Biocon Limited
ARDS, Human, Covid19
Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)
A Phase I, double- blinded, randomized, placebo- controlled study to test the safety of Lomecel-B in Adults suffering from mild to severe acute respiratory distress syndrome (ARDS) due to COVID-19 resultant from 2019-nCoV…
- Trial name
- RECOVER (NCT04629105)
- Testing
- Longeveron Mesenchymal Stem Cells (LMSCs)
- Where
- 3 sites in United States
- Volunteers
- 70 people
- Sponsor
- Longeveron Inc.
Respiratory Distress Syndrome, Adult, Acute Lung Injury
A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury
The purpose of this study is to determine whether sivelestat will reduce the amount of time a patient must spend on a ventilator and/or increase the chance of survival of patients with acute lung injury.
- Trial name
- NCT00036062
- Testing
- Sivelestat
- Where
- 110 sites in United States, Australia and 4 more
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Respiratory Disorders
Safety Study of GSK1995057 Given as Single and Repeat Intravenous Doses in Healthy Subjects.
The main purpose of the study is to see how safe GSK1995057 is and how well it is tolerated after dosing. The study will also investigate how GSK1995057 is taken up, metabolised (chemically broken down), distributed through the…
- Trial name
- NCT01476046
- Testing
- GSK1995057 single dose
- Where
- United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Distress Syndrome
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
The primary objective of this study is to evaluate the safety and tolerability of aerosolized surfactant, specifically lucinactant for inhalation, administered in escalating inhaled doses to preterm neonates 29 to 34 weeks…
- Trial name
- NCT02074059
- Testing
- Lucinactant for Inhalation, nCPAP alone
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- Windtree Therapeutics
Septic Shock, Acute Respiratory Distress Syndrome
CytOSorb TreatMent Of Critically Ill PatientS Registry
Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based…
- Conditions
- Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis
- Trial name
- COSMOS (NCT05146336)
- Testing
- CytoSorb
- Where
- 28 sites in Austria, Germany and 4 more
- Volunteers
- 3,000 people
- Sponsor
- CytoSorbents, Inc
Acute Respiratory Distress Syndrome, ARDS
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with…
- Trial name
- NCT05354141
- Testing
- ExoFlo, Intravenous normal saline
- Where
- 32 sites in United States
- Volunteers
- 970 people
- Sponsor
- Direct Biologics, LLC
Acute Respiratory Distress Syndrome (ARDS)
Safety and Preliminary Efficacy of TISA-818 Injection in Patients With Acute Respiratory Distress Syndrome
This is a randomized, double-blind, placebo-controlled Phase II clinical study of TISA-818-Inj in patients with ARDS to evaluate the safety, preliminary efficacy, and population PK (Pop PK) profile of TISA-818-Inj in adult ARDS…
- Trial name
- NCT07319351
- Testing
- TISA-818-Inj
- Where
- China
- Volunteers
- 57 people
- Sponsor
- EnliTISA (Shanghai) Pharmaceutical Co., Ltd.
Acute Respiratory Distress Syndrome, COVID-19 Acute Respiratory Distress Syndrome
A Randomized Study to Investigate the Effect of Intravenous Imatinib on the Amount of Oxygen in the Lungs and Blood of Adults With COVID-19 Needing Mechanical Ventilation and Supportive Care.
The COVID-19 pandemic has led to an increase in the number of patients admitted to intensive care units (ICU) with acute respiratory distress syndrome (ARDS).
- Conditions
- Acute Respiratory Distress Syndrome, COVID-19 Acute Respiratory Distress Syndrome, Covid19, ARDS
- Trial name
- IMPRESS COVID (NCT04953052)
- Testing
- Imatinib Mesylate
- Where
- 8 sites in India
- Sponsor
- Exvastat Ltd.
Pulmonary Alveolar Proteinosis, Bronchiectasis
Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects
This is a randomized, double-blind, placebo-controlled, single ascending (SAD), and multiple ascending dose (MAD) study conducted at a single clinical site within the UK.
- Conditions
- Pulmonary Alveolar Proteinosis, Bronchiectasis, Cystic Fibrosis, Acute Respiratory Distress Syndrome
- Trial name
- NCT02468908
- Testing
- Molgramostim
- Where
- United Kingdom
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Savara Inc.
Cardio-Respiratory Failure, Extracorporeal Membrane Oxygenation Complication
Safety and Performance of the Novalung Ultimate Kit and Xenios 2.0 During Stationary Use in Hospital and Ground-based Transport of Patients on Extracorporeal Life Support (ECLS)
This prospective observational study will evaluate the safety and performance of the Novalung ultimate kit in combination with the Xenios 2.0 and the MultiSupport Ground during stationary use in hospital and ground-based…
- Conditions
- Cardio-Respiratory Failure, Extracorporeal Membrane Oxygenation Complication, Acute Lung Injury
- Trial name
- Transport+ (NCT07156669)
- Testing
- Novalung ultimate kit, Xenios 2.0, and MultiSupport Ground (MSG)
- Where
- 3 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Xenios AG
COVID-19, ARDS, Human
MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients
This study consists of two parts. Part A (Phase I): A Phase I Double-blind Randomized Placebo-controlled Study in Healthy Subjects to Assess the Safety, Pharmacokinetics, Pharmacodynamics of MRG-001 Part B (Phase 2): A Phase IIa…
- Conditions
- COVID-19, ARDS, Human, Stem Cells, Regeneration
- Trial name
- NCT04646603
- Testing
- MRG-001
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- MedRegen LLC
Respiratory Distress Syndrome, Bronchopulmonary Dysplasia
The Effect of Surfactant Dose on Outcomes in Preterm Infants With RDS
A prospective observational study using de-identified data from the Neonatal Network Research Database (NNRD) supplemented by additional information on dose, method of surfactant administration and dosing frequency to assess…
- Trial name
- OPTI-SURF (NCT03808402)
- Where
- 29 sites in United Kingdom
- Volunteers
- 2,973 people
- Sponsor
- Chiesi UK
COVID-19 Acute Respiratory Distress Syndrome
Safety and Efficacy of Inhaled XW001 For Hospitalized COVID-19 Patients Requiring Oxygen Therapy
This is a multiregional, randomized, double-blind, placebo-controlled Phase 2 study in patients with confirmed symptomatic COVID-19, designed to evaluate the safety, tolerability, efficacy, and PK of XW001 (IL-29 analog)…
- Trial name
- NCT05083117
- Testing
- XW001
- Where
- 2 sites in Argentina, Peru
- Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.
Lung Injury, Acute
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
This is an early phase (Phase IIa), randomized, double-blind, parallel group, multi-centre study for subjects with trauma (physical injury) who are at risk for developing Acute Lung Injury (ALI) or Acute Respiratory Distress…
- Trial name
- NCT00996840
- Testing
- SB-681323 Intravenous 3mg, SB-681323 Intravenous 7.5 mg, SB-681323 Intravenous 7.5mg
- Where
- 6 sites in United States
- Volunteers
- 77 people
- Sponsor
- GlaxoSmithKline
COVID-19, Coronavirus Disease 2019
Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19
It is a multicenter, open-label, randomized, parallel-group study of the efficacy and safety of Tigerase® (GENERIUM JSC, Russia) with standard therapy versus standard therapy in patients with COVID-19.
- Trial name
- NCT04459325
- Testing
- Tigerase® and best available care, Best available care
- Where
- 6 sites in Russia
- Volunteers
- 100 people
- Sponsor
- AO GENERIUM
Acute Lung Injury (ALI) Associated With COVID-19, Inflammatory Lung Conditions Associated With COVID-19
First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19
This is a phase 1 study in healthy subjects to evaluate the safety, tolerability and pharmacokinetics of single (Part A and B) and multiple (Part B) doses of inhaled TD-0903.
- Trial name
- NCT04350736
- Testing
- TD-0903
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Pneumonia, Viral
Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS
The goal of this study is to evaluate the effects of Ibudilast (MN-166) versus placebo in hospitalized patients infected with COVID-19 at risk for developing acute respiratory distress syndrome (ARDS) receiving standard of care…
- Trial name
- NCT04429555
- Testing
- Ibudilast
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- MediciNova
ARDS, Covid19
Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS
This is a randomized, double-blinded, placebo-controlled study of AVM0703 administered as a single intravenous (IV) infusion to patients with moderate or severe immediately life-threatening Acute Respiratory Distress Syndrome…
- Conditions
- ARDS, Covid19, Influenza, Human
- Trial name
- AVM0703 (NCT04366115)
- Testing
- AVM0703
- Volunteers
- 16 people
- Sponsor
- AVM Biotechnology Inc